Polyrizon Ltd.

PLRZ

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$10.30

−US$0.19 · -1.81%

8月21日 16:00 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

44/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Expensive

动量

Neutral

情绪

Mixed

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

行业: Biotechnology
部门: Healthcare
总部: IL
首席执行官: Tomer Izraeli
上市以来: 2024年10月29日
雇员: 6

市场位置

日内区间

当前US$10.30，

US$10.252US$10.86

52周区间

当前US$10.30，

US$2.88US$18.20

开盘价: US$10.625
前收盘价: US$10.49
成交量: 2.09万; 0.4× 平均值
平均成交量: 5.27万; 日均成交量
市值: 1153.82万 USD
贝塔: -1.46; 市场参考 1
50天平均值: US$12.3362; 低于平均水平-16.51%
200天平均值: US$12.1149; 低于平均水平-14.98%

财务数据

财务快照

估值与收益率

企业价值: 1234.82万 USD
市盈率（TTM）: -2.95×
市净率（TTM）: 0.79×
市销率（TTM）: 0×
EV/EBITDA: -2.09×
盈利收益率: -24.42%
自由现金流收益率: -33.21%
股息率: 0.00%

盈利能力和效率

毛利率: 0.00%
营业利润率: 0.00%
净利润率: 0.00%
净资产收益率: -15.89%
资产收益率: -15.56%
投入资本回报率: -29.77%

财务健康

负债权益比: 0×
流动比率: 29.03×

PLRZ 消息

globenewswire.com2026年8月20日

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the…

阅读源码

globenewswire.com2026年7月2日

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,…

阅读源码

globenewswire.com2026年6月29日

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,…

阅读源码

globenewswire.com2026年6月17日

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,…

阅读源码

globenewswire.com2026年6月15日

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function Raanana, Israel,…

阅读源码

globenewswire.com2026年6月10日

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,…

阅读源码